Drug Approval | May 10, 2024
Alembic Pharmaceuticals receives 5 USFDA product approvals in Q1 FY25
Receives 3 final and 2 tentative product approvals thus far in Q1FY25
Receives 3 final and 2 tentative product approvals thus far in Q1FY25
the campaign emphasizes the brand's reliability and effectiveness in providing timely relief
Investing in Malaysia's largest clinic operator to expand the healthcare business
The Unit currently caters to emerging markets of Latin America and Africa with a variety of dosage forms
The brand has also unveiled a new TVC campaign in Telangana and Andhra Pradesh to drive brand awareness
Wipro's MPPP360 platform will assist Independent Health in streamlining the payment process to seamlessly integrate these new provisions
The JV successfully leveraged the strengths of both companies to better serve the fast-growing Indian market
GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07)
First-quarter 2024 revenues totaled $14.9 billion, a decrease of $3.6 billion, or 20%, compared to the prior-year quarter
2024 full-year revenue guidance raised by US$ 2 billion
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
